CA2684174C - Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson - Google Patents
Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson Download PDFInfo
- Publication number
- CA2684174C CA2684174C CA2684174A CA2684174A CA2684174C CA 2684174 C CA2684174 C CA 2684174C CA 2684174 A CA2684174 A CA 2684174A CA 2684174 A CA2684174 A CA 2684174A CA 2684174 C CA2684174 C CA 2684174C
- Authority
- CA
- Canada
- Prior art keywords
- methoxy
- carboxamide
- dichloro
- cyclopropylmethoxy
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000019430 Motor disease Diseases 0.000 title claims abstract description 12
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 11
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title claims description 9
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- -1 3,5-dichloro-1-oxidopyridin-4-yl Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000000095 emetic effect Effects 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 206010001541 Akinesia Diseases 0.000 claims description 2
- 206010006100 Bradykinesia Diseases 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- 208000006083 Hypokinesia Diseases 0.000 claims description 2
- 208000002740 Muscle Rigidity Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000001144 postural effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 206010038743 Restlessness Diseases 0.000 claims 1
- 210000005064 dopaminergic neuron Anatomy 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 6
- 241000282339 Mustela Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- HJORMJIFDVBMOB-GFCCVEGCSA-N (+/-)-Rolipram Chemical compound COC1=CC=C([C@@H]2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-GFCCVEGCSA-N 0.000 description 4
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BLHCCJXRQZPCCG-UHFFFAOYSA-N 3,5-dichloro-4-[4-(cyclopropylmethoxy)-5-methoxy-2H-pyridin-1-yl]-1-oxidopyridin-1-ium Chemical compound C1(CC1)COC1=CCN(C=C1OC)C1=C(C=[N+](C=C1Cl)[O-])Cl BLHCCJXRQZPCCG-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000028436 dopamine uptake Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002895 emetic Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0702853A FR2915100B1 (fr) | 2007-04-19 | 2007-04-19 | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson |
| FR0702853 | 2007-04-19 | ||
| PCT/FR2008/000534 WO2008145841A1 (fr) | 2007-04-19 | 2008-04-16 | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2684174A1 CA2684174A1 (fr) | 2008-12-04 |
| CA2684174C true CA2684174C (fr) | 2014-02-25 |
Family
ID=38712405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2684174A Expired - Fee Related CA2684174C (fr) | 2007-04-19 | 2008-04-16 | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson |
Country Status (33)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104955808A (zh) * | 2012-11-28 | 2015-09-30 | 赛诺菲 | 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型 |
| US9624100B2 (en) | 2014-06-12 | 2017-04-18 | Apple Inc. | Micro pick up array pivot mount with integrated strain sensing elements |
| WO2025080415A1 (en) * | 2023-10-12 | 2025-04-17 | Alto Neuroscience, Inc. | Treatment of neuropsychiatric disorders with tilivapram |
| WO2025079694A1 (ja) * | 2023-10-12 | 2025-04-17 | 株式会社 メドレックス | 経皮吸収組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193926A (en) * | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
| ATE218549T1 (de) * | 1993-07-28 | 2002-06-15 | Aventis Pharma Ltd | Verbindungen als pde iv und tnf inhibitoren |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| ATE290002T1 (de) * | 1999-12-23 | 2005-03-15 | Icos Corp | Cyclische amp spezifische phosphodiesterase inhibitoren |
| EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
| AU2003281219A1 (en) * | 2002-07-02 | 2004-01-23 | Bernard Cote | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| AU2004220456B2 (en) * | 2003-03-12 | 2010-10-14 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
| WO2006135828A2 (en) * | 2005-06-10 | 2006-12-21 | Memory Pharmaceuticals Corporation | Trisubstituted amines as phosphodiesterase 4 inhibitors |
| US20070021451A1 (en) * | 2005-07-20 | 2007-01-25 | Hamamatsu University School Of Medicine | Method for preventing or treating neurologic damage after spinal cord injury |
-
2007
- 2007-04-19 FR FR0702853A patent/FR2915100B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-15 PA PA20088776801A patent/PA8776801A1/es unknown
- 2008-04-16 CN CN2008800126498A patent/CN101663035B/zh not_active Expired - Fee Related
- 2008-04-16 EP EP08787963A patent/EP2146714B1/fr active Active
- 2008-04-16 MY MYPI20094343A patent/MY148092A/en unknown
- 2008-04-16 KR KR1020147033000A patent/KR20150004885A/ko not_active Ceased
- 2008-04-16 CA CA2684174A patent/CA2684174C/fr not_active Expired - Fee Related
- 2008-04-16 BR BRPI0810444A patent/BRPI0810444A2/pt not_active IP Right Cessation
- 2008-04-16 SI SI200830357T patent/SI2146714T1/sl unknown
- 2008-04-16 PT PT08787963T patent/PT2146714E/pt unknown
- 2008-04-16 MX MX2009011284A patent/MX2009011284A/es active IP Right Grant
- 2008-04-16 AT AT08787963T patent/ATE513548T1/de active
- 2008-04-16 RS RS20110358A patent/RS51869B/sr unknown
- 2008-04-16 DK DK08787963.1T patent/DK2146714T3/da active
- 2008-04-16 JP JP2010503549A patent/JP5386478B2/ja not_active Expired - Fee Related
- 2008-04-16 KR KR1020097021593A patent/KR101503942B1/ko not_active Expired - Fee Related
- 2008-04-16 ME MEP-2009-299A patent/ME00935B/me unknown
- 2008-04-16 PL PL08787963T patent/PL2146714T3/pl unknown
- 2008-04-16 NZ NZ580482A patent/NZ580482A/en not_active IP Right Cessation
- 2008-04-16 WO PCT/FR2008/000534 patent/WO2008145841A1/fr not_active Ceased
- 2008-04-16 AU AU2008257322A patent/AU2008257322B2/en not_active Ceased
- 2008-04-16 EA EA200970970A patent/EA019194B1/ru not_active IP Right Cessation
- 2008-04-16 HR HR20110666T patent/HRP20110666T1/hr unknown
- 2008-04-16 ES ES08787963T patent/ES2367408T3/es active Active
- 2008-04-17 TW TW097113997A patent/TWI439269B/zh not_active IP Right Cessation
- 2008-04-17 JO JO2008182A patent/JO2678B1/en active
- 2008-04-18 CL CL2008001136A patent/CL2008001136A1/es unknown
- 2008-04-18 UY UY31035A patent/UY31035A1/es not_active Application Discontinuation
- 2008-04-18 AR ARP080101602A patent/AR066108A1/es unknown
-
2009
- 2009-10-05 US US12/573,326 patent/US20100130554A1/en not_active Abandoned
- 2009-10-11 IL IL201448A patent/IL201448A/en not_active IP Right Cessation
- 2009-10-16 ZA ZA2009/07251A patent/ZA200907251B/en unknown
- 2009-11-10 MA MA32333A patent/MA31367B1/fr unknown
-
2011
- 2011-09-15 CY CY20111100887T patent/CY1111840T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2684174C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
| WO2005034936A1 (en) | Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct | |
| JP2002500651A (ja) | 精神分裂病及び精神病の治療方法 | |
| WO2009156680A2 (fr) | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs | |
| CA2684172C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere | |
| CA2684171C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| JP2005511639A (ja) | 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体 | |
| WO2004037256A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine | |
| WO2025080252A1 (en) | Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one | |
| HK1141725B (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament in the treatment of motor disorders related to parkinson's disease | |
| KR101324689B1 (ko) | 1-(3-클로로페닐)-3-알킬파이퍼라진을 포함하는 식욕 장애 치료용 약학 조성물 | |
| JP2023545367A (ja) | バソプレシン受容体拮抗薬療法の副作用を管理する方法 | |
| KR20240070564A (ko) | 알츠하이머병 예방 또는 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180416 |